SCHEMBL18201818

SCHEMBL18201818

CC(C)(C)OC(=O)N1CC2CN(Cc3ccc(N)nc3)CC2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 3/20 0.45
KCNK9 Q9NPC2 3/20 0.45
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
USP30 Q70CQ3 1/20 0.43
NR1H2 P55055 1/20 0.42
GPR119 Q8TDV5 3/20 0.42
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
HDAC1 Q13547 3/20 0.41
HDAC2 Q92769 3/20 0.41
NAMPT P43490 1/20 0.41
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20311272 0.86 KMT2A (0.52) KCNK3KCNK9NR1H2GPR119HDAC1
SCHEMBL29686606 0.86 NAMPT (0.41) PIK3CAMTORGPR119ALOX5APFEN1
SCHEMBL18201924 0.86 NAMPT (0.41) PIK3CAMTORGPR119ALOX5APFEN1
SCHEMBL1997213 0.85 MEN1 (0.49) GPR119
SCHEMBL30584532 0.85 MEN1 (0.49) GPR119
SCHEMBL18201922 0.83 GPR119 (0.44) KCNK3KCNK9GPR119HDAC1
SCHEMBL18201815 0.83 GPR119 (0.48) KCNK3KCNK9GPR119ALOX5APFEN1
SCHEMBL18201814 0.83 GPR119 (0.48) PIK3CAMTORUSP30GPR119ALOX5AP
SCHEMBL16892002 0.82 KCNK3 (0.49) KCNK3KCNK9USP30NR1H2GPR119
SCHEMBL16892004 0.82 KCNK3 (0.49) KCNK3KCNK9USP30NR1H2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3288931-B2 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2022-07-20 EP disclosed
EP-3288931-B1 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2019-11-06 EP disclosed
EP-3288931-B1 CERTAIN PROTEIN KINASE INHIBITOR CHONGQING FOCHON PHARMACEUTICAL CO LTD (CN) 2019-11-06 EP disclosed
US-10450316-B2 Certain protein kinase inhibitor Chongqing Fochon Pharmaceutical Co., Ltd. (CN) 2019-10-22 US disclosed
US-10450316-B2 Certain protein kinase inhibitor Chongqing Fochon Pharmaceutical Co., Ltd. (CN) 2019-10-22 US disclosed
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR FOCHON BIOSCIENCES, LTD. (CN) 2018-10-11 US disclosed
WO-2016173505-A1 CERTAIN PROTEIN KINASE INHIBITOR SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) 2016-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450316-B2 Certain protein kinase inhibitor CDK4, CDK6, CDK2 KCNK3 4185/4885KCNK9 4049/4885PIK3CA 79/4885
US-20180291027-A1 CERTAIN PROTEIN KINASE INHIBITOR CDK4, CDK6, CDK2 KCNK3 4280/4885KCNK9 4119/4885PIK3CA 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.